ClinicalTrials.gg
Drug

Crizotinib clinical trials

Also written Xalkori, PF-02341066 and PF-2341066.

studies test it
79
open now
10
in phase 3
6
first study started
2006

How each study uses Crizotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Crizotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Aug 2011 · XALKORI · NDA 202570 (FDA, Drugs@FDA)
European Union
23 Oct 2012 · Xalkori · EMEA/H/C/002489 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Crizotinib
63
MET Tyrosine Kinase Inhibitor PF-02341066
13
Alkixen
7
Crizocent
7
Crizotinib 250 MG
3

Brand

Xalkori
32
Xalkori 250 MG
1

Development codes

PF-02341066
26
PF-2341066
13

Studies by the year they started

79 studies that test it; most in 2015 (11)

Studies that test Crizotinib, by start year
YearStudies
20061
20093
201010
20114
20127
20137
20148
201511
20166
20173
20183
20195
20205
20213
20221
20241
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
32
Phase 2
38
Phase 3
6
Phase 4
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 31 · Other 48

Pfizer (29) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (4) · Hunan Province Tumor Hospital (3) · Samsung Medical Center (2) · ECOG-ACRIN Cancer Research Group (1) · Hoffmann-La Roche (1) · University Health Network, Toronto (1)

Often tested with

Tested in the same studies.

Palbociclib (7) · Alectinib (7) · Dasatinib (6) · Sunitinib (6) · Axitinib (6) · Erlotinib (6) · Nivolumab (4) · Trastuzumab (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 10 phase 3 studies under way

Crizotinib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 4

Studies that test Crizotinib.

Studies

Open first, then newest update. How each study uses Crizotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 79

See all 79 studies that test Crizotinib →

Given beside what is tested · 14 — Crizotinib is usual care or a partner of the new treatment
As the comparator · 15 — what is tested is compared with Crizotinib

Codes

What other systems call Crizotinib · ClinicalTrials.gg INT006744

  • MeSH (NLM) D000077547CrizotinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 53AH36668SCRIZOTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1148495Confirmed FDA, Wikidata
  • Wikidata Q5186964crizotinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C74061CrizotinibOne source FDA
  • DrugBank DB08865One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.